Elisa Mokany has more than 15 years experience in medical research, during which she has been involved in developing analytical tests and novel technologies for molecular diagnostics. Previously, she worked for St Vincent’s hospital developing tests for the diagnosis of colorectal cancer. Later Elisa worked at Johnson & Johnson Research Pty Limited (JJR) where she developed diagnostic tests for leukemia and was involved in the commercialisation of proprietary technology known as DzyNA PCR. While at JJR, Elisa undertook studies towards her PhD, which involved co-invention of the novel nucleic acid technology, MNAzymes. The MNAzyme technology is key to the portfolio of intellectual property which underpinsSpeeDx Pty Ltd, of which she is a founder. Elisa is the Director of Research and Development at SpeeDx and in this role she manages research projects, coordinates technology evaluations and transfers, and disseminates information to the medical and scientific community, in Australia and overseas. Elisa is an inventor on 8 patents/patent applications involving nucleic acid analysis including the novel PASS technology which has multiple applications in the in vitro diagnostic field. Elisa studied at the University of NSW, obtaining a BSc (Hons 1st Class) and later completed her PhD at JJR in conjunction with the School of Biotechnology and Biomolecular Science at the University of New South Wales.